A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injector

Start Date03 Mar 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07206290

/ Not yet recruitingPhase 2

Albuminuria Reduction Trial and Investigation With Survodutide Treatment in CKD

The ARTIST-CKD trial is a clinical study evaluating the effect of weekly subcutaneous administration of survodutide (3.6 mg) on kidney function in patients with chronic kidney disease (CKD) and elevated albuminuria. The primary objective is to determine whether survodutide leads to early, sustained, and clinically meaningful reductions in albuminuria, regardless of diabetes status.

Start Date02 Mar 2026

Sponsor / Collaborator

Universitair Medisch Centrum Groningen

NCT07221591

/ Active, not recruitingPhase 1

Relative Bioavailability of Two Survodutide (BI 456906) Formulations When Administered Subcutaneously Via Pre-filled Syringe Over 28 Weeks (an Open-label, Randomised, Multiple Dose, Parallel Group Trial)

This study is open to healthy people between 18 and 65 years of age. People can join the study if they have a body mass index between 27 and 39.9 kg/m2.
The purpose of this study is to test a new formulation of a medicine called survodutide. Survodutide is being developed to help people with obesity and people with liver conditions. When a new formulation is developed, it is important to understand how it is taken up by the body.
Participants are divided into 2 groups by chance. One group gets the reference formulation of survodutide (formulation A). The other group gets the new formulation of survodutide (formulation B2). Participants in both groups inject survodutide under their skin once a week for about 6 and a half months.
Participants are in the study for about 7 months. During this time, they visit the study site 15 times. For one of the visits, participants stay overnight for 3 nights at the study site. The site staff takes blood samples to measure how much survodutide is in the blood. They also check participants' health and take note of any unwanted effects.

Start Date05 Nov 2025

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Survodutide

100 Translational Medicine associated with Survodutide

100 Patents (Medical) associated with Survodutide

Literatures (Medical) associated with Survodutide

01 Jan 2026·Endocrinology, diabetes & metabolism

Comparative Analysis of Glucagon Receptor Agonists vs. Resmetirom in MASLD and MASH: Network Meta‐Analysis of Clinical Trials

Review

Author: Hodrob, Tamer ; Andonie, Celina R. ; Ladadweh, Mahmoud ; Ayesh, Hazem ; Abusalameh, Alaaeddin ; Ismail, Ibrahim

ABSTRACT:

Background:

MASLD and its progressive form MASH represent a global public health challenge due to their rising prevalence and their possible progression to cirrhosis and HCC. Resmetirom, dual (e.g., cotadutide, survodutide), and triple GRAs (e.g., retarutide) have demonstrated potential efficacy in recent clinical trials. This network meta‐analysis evaluates the comparative efficacy and safety of these treatments.

Methods:

We systematically searched PubMed, Scopus, ClinicalTrials.gov , and Cochrane Central for randomised controlled trials evaluating these medications versus placebo in adults with MASLD and MASH. The outcomes assessed included changes in ALT, AST, LDL, and HDL levels, changes in MRI‐PDFF, safety outcomes (diarrhoea, fatigue, and nausea), serious adverse events, ELF, adiponectin, and MASH resolution with no worsening of fibrosis. Random‐effects model and network meta‐analysis methods were employed.

Results:

Six trials met the inclusion criteria. GRAs significantly reduced ALT levels with MD of −22.10, while resmetirom demonstrated the greatest reduction in AST levels with a MD of −13.17. Resmetirom also led to a borderline significant increase in HDL with the most significant reduction in LDL levels. Moreover, GRAs showed a significant effect on MRI‐PDFF with a MD of −46.09. Overall, resmetirom showed a more favourable safety profile. In addition, GRAs significantly decreased ELF scores, resmetirom significantly improved MASH resolution without worsening of fibrosis, and both treatments significantly increased adiponectin.

Conclusion:

GRAs superiorly reduce ALT levels, MRI‐PDFF, and ELF. Resmetirom significantly reduces AST, HDL, and LDL levels, increases MASH resolution without worsening of fibrosis, and offers a more favourable safety profile. Both GRAs and resmetirom significantly increase adiponectin.

01 Jan 2026·PHARMACOLOGICAL RESEARCH

IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes

Review

Author: Hardaway, J Andrew ; Habegger, Kirk ; Elmendorf, Andrew J ; Flak, Jonathan N ; Kim, Il-Man ; Yousefian, Mostafa

The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation of treatment, the amount of which can depend on the treatment and patient, iterative advancements may improve weight loss durability in the long term. In this review, we discuss the development of glucagon like peptide-1 receptor (GLP-1R) agonists and GLP-1R/ glucose-dependent insulinotropic polypeptide receptor (GIPR) co-agonists, and how future generations will leverage this strategy. We focus our review on glucagon receptor (GCGR) agonism, which has recently been combined with both GLP-1R and GLP-1R/GIPR agonism to generate dual (e.g. survodutide, cotatutide, mazdutide, etc) and triple agonists (e.g. retatrutide, etc) for improved body weight loss via energy expenditure stimulation. We rely on largely pre-clinical evidence for action because clinical data is extremely limited for GCGR agonism. Herein, we review mechanisms by which glucagon receptor agonists act to increase energy expenditure. Finally, we discuss future improvements to incretin-based therapeutics, and how they can include strategies that target the GCGR. The purpose of this review is to discuss mechanisms by which GCGR agonism can reduce body weight and put them in the context of the combination with incretin receptor agonists. Mechanistic data has only currently been evaluated in preclinical rodent models and evidence for similar processes in humans is limited. We also provide perspectives about how treatments can improve for future advancement of obesity treatment.

01 Jan 2026·DIABETES OBESITY & METABOLISM

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial ( SYNCHRONIZE ™‐1)

Article

Author: Bleckert, Gabriele ; Platz, Elke ; le Roux, Carel W. ; Startseva, Elena ; Brueckmann, Martina ; Kaplan, Lee M. ; Bozkurt, Biykem ; Wharton, Sean ; Ajaz Hussain, Samina ; Kloer, Isabel M.

Abstract:

Aims:

Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of participants in the SYNCHRONIZE‐1 trial in adults with obesity without T2D ( ClinicalTrials.gov : NCT06066515).

Materials and methods:

Participants aged ≥18 years with BMI ≥30 or ≥27 kg/m 2 with ≥1 obesity complication without T2D were randomized 1:1:1 to double‐blind, once‐weekly, subcutaneous injections of survodutide (up‐titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. The primary endpoints are percent body weight change and achievement of body weight reduction ≥5% from baseline to Week 76. Efficacy and safety analyses will include all randomized and treated participants.

Results:

At baseline, participants ( n = 725 from 14 countries) had a mean age of 47.1 years, BMI 37.9 kg/m 2 , and waist circumference 115.2 cm. Most participants (59.4%) were female; 47.3% were from North America, 21.0% from Europe, and 20.0% from East Asia. Obesity complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). Mean haemoglobin A1c was 5.5%, estimated glomerular filtration rate 93.0 mL/min/1.73 m 2 , systolic/diastolic blood pressure 127.0/82.7 mmHg, and low‐density lipoprotein cholesterol 116.4 mg/dL; 21.8% were taking lipid‐lowering drugs.

Conclusions:

SYNCHRONIZE‐1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP‐1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.

137

News (Medical) associated with Survodutide

11 Dec 2025

·www.fiercebiotech.com

Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech

Zealand Pharma put today’s deal with OTR Therapeutics in the context of an updated strategy dubbed “Metabolic Frontier 2030.”\n OTR Therapeutics may still be keeping its own pipeline under wraps, but Zealand Pharma has seen enough promise in the Chinese biotech’s platform to agree to up to $30 million in upfront payments.Zealand wants to use OTR’s oral small-molecule platform to “discover and develop novel therapeutics for multiple targets in metabolic diseases,” according to a Dec. 11 release. In return, the Danish drug developer has agreed to hand over $20 million upfront—rising to $30 million “under certain pre-agreed conditions,” according to the release.Beyond that, OTR will be eligible for preclinical, development, regulatory and commercial milestone payments that could reach $2.5 billion “with the majority representing commercial milestones.” The Chinese company will also be in line for tiered single-digit royalties on worldwide sales should a drug eventually make it to market.Zealand put this morning’s deal in the context of an updated strategy dubbed “Metabolic Frontier 2030.” The road map includes targeting five product launches by 2030 as well as evolving “industry-leading cycle times from idea to clinic.”The ultimate goal is to become a “generational biotech leader in obesity and metabolic health,” the company explained in a separate release this morning.Zealand’s pipeline includes the phase 2-stage Roche-partnered amylin analogue petrelintide as well as the phase 3-stage glucagon/GLP-1 receptor dual agonist survodutide, which is in development with Boehringer Ingelheim.Last month, Zealand hit pause on one of its obesity candidates, known as dapiglutide, as the company strives to focus its time and money on “programs with the greatest potential for clinical differentiation and long-term value creation.”Zealand Chief Scientific Officer Utpal Singh, Ph.D., said the multiprogram pact with OTR “will expand our metabolic health pipeline into oral small-molecule therapeutics for targets where we have deep biological expertise, complementing our strong peptide R&D platform.” “This partnership is an early testament—with more to follow—to the execution of our updated strategy to further strengthen and evolve our platform, broadening treatment options for people living with overweight, obesity, and other metabolic diseases,” Singh added. “We are confident the partnership with OTR Therapeutics will be highly productive in achieving our shared goal of expanding treatment options for people living with metabolic diseases.”We still don’t know too much about OTR. The Shanghai-based company—which only launched back in March—has so far kept its pipeline under wraps, only disclosing that it covers “differentiated programs that target significant treatment gaps in immunology and inflammation, oncology and other disease areas,” such as cardiometabolic conditions.OTR also revealed last week that it had raised a $100 million series A back in June, backed by the likes of Pfizer Ventures. The biotech—which is already a member of the Bayer Co.Lab life sciences incubator network—is using the series A funds to expand the capability of its hub in Shanghai\'s Zhangjiang Hi-Tech Park.OTR’s founder and CEO Zhui Chen, Ph.D., said this morning’s pact “represents a strong endorsement of our proprietary platform and strategic vision, and our proven ability to drive innovation and deliver quality and speed in execution.”“By combining our strengths in innovative drug discovery and development with Zealand Pharma’s deep expertise in the disease area, we are well positioned to discover potentially transformative therapies for patients worldwide,” the CEO added.

11 Dec 2025

·endpoints.news

Zealand inks deal with Chinese biotech as it spells out broader metabolic disease ambitions

Zealand Pharma is spending at least $20 million upfront to discover and develop new targets for metabolic diseases together with Shanghai-based biotech OTR Therapeutics. The deal is part of the Danish drugmaker’s new plans announced Thursday to become a “generational biotech leader” in obesity and metabolic diseases, with the aim of five market launches and expanding its clinical pipeline to include more than ten programs by 2030. Under the deal with OTR, Zealand’s upfront commitment could increase to $30 million under certain conditions. OTR is also eligible for up to $2.5 billion in milestones, as well as tiered royalties on future sales. OTR will use its discovery platform to identify several new targets for metabolic diseases and complete preclinical work, with the Danish biotech expected to take over clinical development. Last month, Zealand CEO Adam Steensberg told Endpoints News that the company was ready to ramp up partnerships with smaller biotechs. He also urged industry to move away from the “weight loss Olympics,” or a fixation on achieving ever-higher percentages of weight loss, and instead encouraged a more nuanced approach to improving on current treatment options. Zealand’s deal with OTR comes the same day it plans to unwrap its new business strategy called the “Metabolic Frontier 2030” at an event in London. Besides plans for five launches and pipeline expansion, Zealand is also preparing to build a new research site in the US. “By establishing a cutting-edge Boston research site, we are putting advanced automation and AI to work alongside more than 25 years of unmatched peptide expertise to accelerate drug discovery and development, while expanding our molecule-making toolbox,” Steensberg said in the release. Zealand is awaiting several important readouts next year, including Phase 2 data for its Roche-partnered amylin analog, petrelintide, in patients who are overweight or obese. Unlike GLP-1 agonists, amylin analogs increase feelings of fullness by restoring sensitivity to the satiety-promoting hormone leptin, according to Zealand. They’re expected to have better tolerability and the potential to preserve muscle mass better than available treatments. Zealand is also expecting Phase 3 data next year for its Boehringer Ingelheim-partnered GLP-1/glucagon receptor dual agonist, survodutide, in overweight or obese patients with metabolic dysfunction-associated steatohepatitis (MASH). Earlier this month, OTR Therapeutics said it raised $100 million after being founded in March. Its model of tapping into the speed and flexibility of clinical development processes in China to develop a mix of assets from inside and outside the country has already attracted interest from several large drugmakers. Besides cardiometabolic diseases, it is also focused on oncology, immunology and inflammation.

Phase 2Phase 3

11 Dec 2025

·www.globenewswire.com

Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health

Press release – No. 19 / 2025 Zealand Pharma outlines Metabolic Frontier 2030 strategy to become a generational biotech leader in obesity and metabolic health Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 data with petrelintide in Q1 2026 and Phase 3 obesity data with survodutide throughout 2026New research site in Boston to combine our +25-year peptide heritage with AI-driven drug discovery, advanced automation, and next-generation molecule creation Copenhagen, Denmark, December 11, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today presents its strategy for redefining the near-term future of weight management and its vision to establish leadership in metabolic health at its Capital Markets Day in London. The Company will unveil its comprehensive strategy that combines strategic partnerships, accelerated drug development, and expanded research capabilities to build the world’s most valuable metabolic health pipeline. Zealand Pharma will target five launches, a robust clinical pipeline of more than ten programs, and industry-leading cycle times from idea to clinic by 2030. By leveraging its unrivaled peptide expertise, strengthened organization, and expanded global research capabilities, alongside advanced computational methods and partnerships, Zealand Pharma will accelerate its drug discovery process and expand its molecule-making toolbox. This strategic approach, combined with five anticipated launches from the existing pipeline and the Company's robust financial foundation, will optimally position Zealand Pharma to achieve leadership in metabolic health. “Today marks a pivotal moment for Zealand Pharma as we unveil our aim to build a generational biotech company that will fundamentally transform how we treat obesity and metabolic disease,” said Adam Steensberg, Chief Executive Officer of Zealand Pharma. “We are redefining weight management for a new era - moving beyond the Weight loss Olympics toward solutions that support the everyday needs, aspirations, and overall well-being of people living with overweight, obesity, and metabolic imbalance. “Through Metabolic Frontier 2030 and beyond, we are committed to addressing some of the greatest healthcare challenges of our time. Our strategy is built to enable multiple waves of innovation in metabolic health - from our foundational amylin franchise to breakthrough approaches that will not only shatter the adherence ceiling observed with current medicines in obesity but deliver a world-class metabolic health pipeline. “By establishing a cutting-edge Boston research site, we are putting advanced automation and AI to work alongside more than 25 years of unmatched peptide expertise to accelerate drug discovery and development, while expanding our molecule-making toolbox. This includes advancing oral small-molecule receptor agonists through our collaboration with OTR Therapeutics for validated targets within Zealand Pharma’s established areas of biological expertise. Together, these initiatives - with more to come - enable us to deliver on our strategy and continue advancing innovative solutions for people with overweight, obesity, and metabolic imbalance.” The event today will feature speakers from Zealand Pharma’s leadership team, alongside external experts and thought leaders in obesity and metabolism: Zealand Pharma speakers Adam Steensberg, Chief Executive OfficerHenriette Wennicke, Chief Financial OfficerDavid Kendall, Chief Medical OfficerEric Cox, Chief Commercial OfficerUtpal Singh, Chief Scientific Officer External experts Dr. Carel Le Roux, MBChB, MSC, FRCP, FRCPath, PhD, Professor of Experimental Pathology at University College DublinJonathan Roth, PhD, Metabolic researcher and pioneer in amylin-leptin biologyLouis J. Aronne, MD, FACP, DABOM, Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medical College The Capital Markets Day will begin at 13:00 GMT and can be viewed via live webcast by registering here: https://zealand-pharma-capital-markets-day-dec-25.open-exchange.net/registration. A replay will be available on the company's website under Investors and Events & Presentations following the event. About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com. Forward-looking statementsThis press release contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@zealandpharma.com Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@zealandpharma.com Rachel James-Owens (Media)Vice President, Corporate Communications and Media RelationsZealand PharmaRJamesOwens@zealandpharma.com Amber Fennell, Jessica Hodgson, Sean Leous (Media)ICR HealthcareZealandPharma@icrhealthcare.com+44 (0) 7739 658 783

Phase 2

100 Deals associated with Survodutide

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fibrosis, Liver	Phase 3	United States	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	China	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Japan	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Argentina	Boehringer Ingelheim (China) Investment Co., Ltd.	14 Oct 2024
Fibrosis, Liver	Phase 3	Argentina	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Australia	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Austria	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Belgium	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Brazil	Boehringer Ingelheim GmbH	14 Oct 2024
Fibrosis, Liver	Phase 3	Bulgaria	Boehringer Ingelheim GmbH	14 Oct 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04771273 (1404-0043, CTgov)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	295	Survodutide (Survodutide 2.4 mg - Planned Maintenance Treatment)	qxfxrajkdv = dznrtxihsj fqwhsowdyd (zttifounee, wkepsfzpqs - wwylxqasrc) View more	-	03 Dec 2024
				Survodutide (Survodutide 4.8 mg - Planned Maintenance Treatment)	qxfxrajkdv = zgtldoosze fqwhsowdyd (zttifounee, uiucejaimo - fbrhgqvfvl) View more
ESC2024	Phase 2	Obesity	387	Survodutide 4.8 mg	pvbhcserkf(baahfsdncs) = cdjscepkya jhzafxjikn (bklhiusmll )	Positive	01 Sep 2024
NCT04153929 \| NCT03591718 \| NCT04667377 (1665-P, ADA2024)	Phase 1/2	Diabetes Mellitus, Type 2 \| Obesity HbA1c \| insulin sensitivity \| glucose biomarkers ... View more	-	Survodutide	phctvmgfmq(tymqetfgrq) = 0.4 vs 0.0 glphzgrjsv (eeiqescoms ) View more	Positive	14 Jun 2024
				Placebo
NCT04771273 (1404-0043, Pubmed)	Phase 2	Metabolic Dysfunction Associated Steatohepatitis	293	Survodutide 2.4 mg	fihxfqxbqs(knssinmcwl) = hsjpptoeam ehhwqaxecz (jiajpnvvtv ) View more	Positive	07 Jun 2024
				Survodutide 4.8 mg	fihxfqxbqs(knssinmcwl) = tmlcioemqa ehhwqaxecz (jiajpnvvtv ) View more
NCT04667377 (Phase II Trial, ENDO2024)	Phase 2	Overweight \| Obesity	384	Survodutide 4.8 mg	llmvqbmhzv(tcypgcajus) = nogrmcvdvl xywguqvtih (wnihtbheno )	Positive	01 Jun 2024
				Placebo	llmvqbmhzv(tcypgcajus) = nnzuetpgsx xywguqvtih (wnihtbheno )
NCT04771273 (GlobeNewswire) Manual	Phase 3	Metabolic Dysfunction Associated Steatohepatitis	-	survodutide	fhbkfvtjpe(sznoapeven) = sfmkvqrvuk iftggmcqgc (medlplqqcg ) Met	Positive	26 Feb 2024
				Placebo	fhbkfvtjpe(sznoapeven) = zuyzepvpba iftggmcqgc (medlplqqcg ) Met
NCT04771273 (Corporate Publications) Manual	Phase 2	Metabolic dysfunction-associated steatotic liver disease	295	Survodutide	rrydsxpjfd(lkxgrlgktn) = hxusmhihwt khgveswolo (nevvvlkfaq ) Met	Positive	26 Feb 2024
				placebo	rrydsxpjfd(lkxgrlgktn) = cowvcrmlsj khgveswolo (nevvvlkfaq ) Met
NCT04667377 (Phase II Trial, CTgov)	Phase 2	Obesity	387	BI 456906 (0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))	xjmsxyupdr(eztzzusijm) = nwubspkbri zqexngafdb (hwqsqstjaq, 1.07) View more	-	02 Nov 2023
				BI 456906 (2.4 mg BI 456906 - Planned Maintenance Treatment)	xjmsxyupdr(eztzzusijm) = ssoktjiafj zqexngafdb (hwqsqstjaq, 1.01) View more
NCT04667377 (ADA2023) Manual	Phase 2	Overweight \| Obesity	387	BI 456906 0.6 mg	devsecwvbn(cfdqmbesuc) = kcvtsvcigo ziuvtzcoei (kjofclyanj ) View more	Positive	23 Jun 2023
				BI 456906 2.4 mg	devsecwvbn(cfdqmbesuc) = grvnmxmuii ziuvtzcoei (kjofclyanj ) View more
NCT04153929 (Phase II, CTgov)	Phase 2	Diabetes Mellitus, Type 2	413	Placebo (Placebo)	hshpffkfha(gpzyyaxfvt) = ydzspfcmoz xibezxrjko (jwykazlhaq, 0.81) View more	-	29 Nov 2022
				BI 456906 (BI 456906 0.3 mg)	hshpffkfha(gpzyyaxfvt) = xarqylewcy xibezxrjko (jwykazlhaq, 0.71) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis